PDCD1 and melanoma: However, a clinical trial demonstrated that the combination of guadecitabine and ipilimumab was safe in patients with unresectable stage III/IV melanoma and that it upregulates HLA class I in melanoma cells and enhances antitumor immunity as demonstrated by an increase in CD8+ PD-1+ T cells and CD20+ B cells [117].